Search

Search Constraints

You searched for: Author/Creator Zaman, Khalil

Search Results

1. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. Issue 4 (April 2021)

2. Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment. (December 2020)

3. Current challenges and unmet needs in treating patients with human epidermal growth factor receptor 2-positive advanced breast cancer. (December 2022)

4. Eribulin as first-line treatment in older patients with advanced breast cancer: A multicenter phase II trial [SAKK 25/14]. Issue 1 (January 2023)

5. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Issue 1 (January 2018)

6. Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: A multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08. Issue 10 (July 2015)

7. Intraductal patient‐derived xenografts of estrogen receptor α‐positive breast cancer recapitulate the histopathological spectrum and metastatic potential of human lesions. Issue 3 (27th December 2018)

8. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Issue 5 (May 2020)

9. Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer. (December 2022)

10. Oncological care organisation during COVID-19 outbreak. Issue 4 (26th August 2020)